摘要
目的探讨胰岛素样生长因子(IGF)结合蛋白2,3(IGFBP-2,-3)在卵巢上皮性癌(简称卵巢癌)患者血液和卵巢肿瘤组织中的表达,及其与卵巢癌临床病理学特征的关系。方法采用Western ligand blot和Western blot检测卵巢肿瘤患者及正常对照者(卵巢良性肿瘤10例,交界性肿瘤6例,卵巢癌10例,正常对照者10例)血清中IGFBP-2、IGFBP-3及IGF-Ⅱ含量;免疫组织化学染色检测正常卵巢组织(4例)和卵巢肿瘤组织中(卵巢良性肿瘤8例,卵巢交界性肿瘤8例,卵巢癌23例,包括中度和高度分化者15例,低度分化者8例)IGFBP-2,-3的表达。结果卵巢癌患者血清大片段以及成熟IGF-Ⅱ均明显降低,IGFBP-2水平明显升高,而IGFBP-3含量明显降低甚至消失,与相应正常对照组、良性或交界性组相比差异均有统计学意义(P<0.001或P<0.01)。免疫组织化学染色结果显示卵巢癌IGFBP-2的表达明显升高(P<0.0001或P<0.005),且随着卵巢癌组织分化程度的降低,IGFBP-2的表达呈增强趋势;而IGFBP-3的表达随着卵巢癌细胞分化程度的降低,明显降低或呈阴性表达(P<0.05)。结论卵巢癌患者血循环中IGFBP-3降解以及IGFBP-2明显升高的状况有可能导致IGF-Ⅱ生物学功能改变,并与卵巢癌的临床病理学特征有明显的相关性。
Objective To explore the serum levels of IGFBP-2,-3 and their proper roles in the regulation of IGF- Ⅱ bioavailability in patients with ovarian tumor, and to investigate the correlation between the expressions of IGFBP-2 and IGFBP-3 in ovarian tumor tissues and related clinicopathological characteristics. Methods Serum levels of IGFBP-2 ,-3 and big/mature IGF-Ⅱ were measured by Western ligand blot （WLB） and Western blot（WB） in patients with ovarian tumor （10 cases of benign tumor, 6 cases of borderline tumor and 10 cases of malignant tumor） and 10 cases of normal control. The expressions of IGFBP-2 and IGFBP-3 were examined in 39 specimens of ovarian tumor （8 cases of benign tumor, 8 cases of borderline tumor and 23 cases of malignant tumor） and 4 cases of normal ovarian tissues by immunohistoehemical staining. Results The serum levels of both big and mature IGF-Ⅱ in epithelial ovarian cancer （ovarian cancer） patients were significantly decreased compared with those of normal control and benign and borderline tumor（P〈0. 001 or P〈0. 01）. The increased serum level of IGFBP-2 and decreased IGFBP-3 level were observed in patients with malignant ovarian tumors by comparing with those of patients with normal controls,benign and borderline tumor（P〈0. 001 or P〈0.01）. The expression of IGFBP-2 was significantly higher in malignant ovarian tumor tissues than those in normal control and benign ovarian tumors tissues （P〈0. 0001 ,P〈0. 001, and the expression of IGFBP-3 decreased significantly in lower differentiated ovarian cancer tissues compared with that in high and moderate differentiated ovarian cancer tissues（P〈0.05）. Concluion IGFBP-2 predominantly presents in the circulation of malignant patients in contrast to IGFBP-3, which may result in altered bioavailability of IGF-Ⅱ in ovarian cancer, leading to the progress of tumor. The serum levels of both IGFBP-2 and IGFBP-3 and their expressions in tumor tissues are correlated with the clinicopathological characteristi
出处
《四川大学学报（医学版）》
CAS
CSCD
北大核心
2009年第4期639-643,共5页
Journal of Sichuan University(Medical Sciences)
基金
河北省自然科学基金(批准号C2008000934)资助
关键词
卵巢癌
胰岛素样生长因子-2
胰岛素样生长因子结合蛋白2
3
免疫组织化学
Epithelial ovarian cancer Insulin-like growth factor Ⅱ （IGF-Ⅱ ） factor-binding protein 2 （IGFBP-2） Insulin-like growth factor-binding protein Immunochemistry Insulin-like growth 3 （IGFBP-3）
